The latest price target for IGM Biosciences (NASDAQ:IGMS) was reported by JP Morgan on January 13, 2025. The analyst firm set a price target for $0.00 expecting IGMS to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for IGM Biosciences (NASDAQ:IGMS) was provided by JP Morgan, and IGM Biosciences upgraded their neutral rating.

The last upgrade for IGM Biosciences Inc happened on January 13, 2025 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for IGM Biosciences Inc.

The last downgrade for IGM Biosciences Inc happened on January 10, 2025 when Jefferies changed their price target from $48 to $2 for IGM Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGM Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGM Biosciences was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

While ratings are subjective and will change, the latest IGM Biosciences (IGMS) rating was a upgraded with a price target of $0.00 to $0.00. The current price IGM Biosciences (IGMS) is trading at is $1.77, which is out of the analyst’s predicted range.